Which has stronger valuation & earnings, BIIB or AMGN?

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.07 $1.29B $9.32 22.10 Amgen $36.75B 5.38 $7.71B $14.37 25.49

Is BIIB or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Biogen's net margin of 13.81%. Amgen's return on equity of 137.41% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 13.81% 12.83% 8.01% Amgen 20.96% 137.41% 13.28%

Does the media refer more to BIIB or AMGN?

In the previous week, Biogen had 22 more articles in the media than Amgen. MarketBeat recorded 60 mentions for Biogen and 38 mentions for Amgen. Amgen's average media sentiment score of 1.15 beat Biogen's score of 0.79 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 30 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 29 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BIIB or DNLI?

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.07 $1.29B $9.32 22.10 Denali Therapeutics $330.53M 11.18 -$512.54M -$2.88 N/A

Does the media prefer BIIB or DNLI?

In the previous week, Biogen had 54 more articles in the media than Denali Therapeutics. MarketBeat recorded 60 mentions for Biogen and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.80 beat Biogen's score of 0.79 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 30 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive Denali Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GILD or BIIB?

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 5.66 $8.51B $7.34 18.29 Biogen $9.89B 3.07 $1.29B $9.32 22.10

Is GILD or BIIB more profitable?

Gilead Sciences has a net margin of 30.99% compared to Biogen's net margin of 13.81%. Gilead Sciences' return on equity of 48.19% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences 30.99% 48.19% 18.28% Biogen 13.81% 12.83% 8.01%

Does the media prefer GILD or BIIB?

In the previous week, Biogen had 28 more articles in the media than Gilead Sciences. MarketBeat recorded 60 mentions for Biogen and 32 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.99 beat Biogen's score of 0.79 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 20 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 30 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BIIB or IONS?

In the previous week, Biogen had 33 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 60 mentions for Biogen and 27 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.79 beat Ionis Pharmaceuticals' score of 0.05 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 30 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive Ionis Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, MRNA or BIIB?

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $2.20B 11.13 -$2.82B -$8.15 N/A Biogen $9.89B 3.07 $1.29B $9.32 22.10

Is MRNA or BIIB more profitable?

Biogen has a net margin of 13.81% compared to Moderna's net margin of -143.55%. Biogen's return on equity of 12.83% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Biogen 13.81% 12.83% 8.01%

Does the media favor MRNA or BIIB?

In the previous week, Biogen had 48 more articles in the media than Moderna. MarketBeat recorded 60 mentions for Biogen and 12 mentions for Moderna. Biogen's average media sentiment score of 0.79 beat Moderna's score of 0.22 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Biogen 30 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive

Biogen (BIIB) Competitors

$205.99 -2.93 (-1.40%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$205.05 -0.94 (-0.46%)

As of 07/17/2026 07:19 PM Eastern

Compare

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

Should you buy Biogen stock or one of its competitors? MarketBeat compares Biogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biogen include Amgen (AMGN), Denali Therapeutics (DNLI), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), and Moderna (MRNA). These companies are all part of the "medical" sector.

How does Biogen compare to Amgen?

Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Biogen has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Amgen has a net margin of 20.96% compared to Biogen's net margin of 13.81%. Amgen's return on equity of 137.41% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Amgen	20.96%	137.41%	13.28%

In the previous week, Biogen had 22 more articles in the media than Amgen. MarketBeat recorded 60 mentions for Biogen and 38 mentions for Amgen. Amgen's average media sentiment score of 1.15 beat Biogen's score of 0.79 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	30 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	29 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.07	$1.29B	$9.32	22.10
Amgen	$36.75B	5.38	$7.71B	$14.37	25.49

Biogen presently has a consensus price target of $220.04, suggesting a potential upside of 6.82%. Amgen has a consensus price target of $356.62, suggesting a potential downside of 2.64%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Summary

Amgen beats Biogen on 12 of the 17 factors compared between the two stocks.

How does Biogen compare to Denali Therapeutics?

Biogen (NASDAQ:BIIB) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.07	$1.29B	$9.32	22.10
Denali Therapeutics	$330.53M	11.18	-$512.54M	-$2.88	N/A

Biogen presently has a consensus price target of $220.04, suggesting a potential upside of 6.82%. Denali Therapeutics has a consensus price target of $35.08, suggesting a potential upside of 50.64%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Biogen has a net margin of 13.81% compared to Denali Therapeutics' net margin of 0.00%. Biogen's return on equity of 12.83% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Denali Therapeutics	N/A	-52.20%	-43.86%

In the previous week, Biogen had 54 more articles in the media than Denali Therapeutics. MarketBeat recorded 60 mentions for Biogen and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.80 beat Biogen's score of 0.79 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	30 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
Denali Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biogen has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Summary

Biogen beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Biogen had 28 more articles in the media than Gilead Sciences. MarketBeat recorded 60 mentions for Biogen and 32 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.99 beat Biogen's score of 0.79 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	20 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	30 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of 30.99% compared to Biogen's net margin of 13.81%. Gilead Sciences' return on equity of 48.19% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Biogen	13.81%	12.83%	8.01%

Gilead Sciences presently has a consensus price target of $159.04, suggesting a potential upside of 18.44%. Biogen has a consensus price target of $220.04, suggesting a potential upside of 6.82%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	3 Hold rating(s)	26 Buy rating(s)	0 Strong Buy rating(s)	2.90
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.66	$8.51B	$7.34	18.29
Biogen	$9.89B	3.07	$1.29B	$9.32	22.10

Gilead Sciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Summary

Gilead Sciences beats Biogen on 12 of the 17 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Biogen has a net margin of 13.81% compared to Ionis Pharmaceuticals' net margin of -30.91%. Biogen's return on equity of 12.83% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.07	$1.29B	$9.32	22.10
Ionis Pharmaceuticals	$944M	9.52	-$381.39M	-$2.07	N/A

Biogen has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biogen presently has a consensus price target of $220.04, indicating a potential upside of 6.82%. Ionis Pharmaceuticals has a consensus price target of $96.05, indicating a potential upside of 76.59%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Biogen had 33 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 60 mentions for Biogen and 27 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.79 beat Ionis Pharmaceuticals' score of 0.05 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	30 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Biogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Biogen compare to Moderna?

Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Moderna currently has a consensus target price of $38.27, suggesting a potential downside of 38.10%. Biogen has a consensus target price of $220.04, suggesting a potential upside of 6.82%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55

In the previous week, Biogen had 48 more articles in the media than Moderna. MarketBeat recorded 60 mentions for Biogen and 12 mentions for Moderna. Biogen's average media sentiment score of 0.79 beat Moderna's score of 0.22 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	30 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	11.13	-$2.82B	-$8.15	N/A
Biogen	$9.89B	3.07	$1.29B	$9.32	22.10

Biogen has a net margin of 13.81% compared to Moderna's net margin of -143.55%. Biogen's return on equity of 12.83% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Biogen	13.81%	12.83%	8.01%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Summary

Biogen beats Moderna on 14 of the 17 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIIB vs. The Competition

Export

Metric	Biogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.41B	$3.69B	$6.87B	$12.29B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	22.10	21.03	27.25	23.92
Price / Sales	3.07	178.36	494.84	75.61
Price / Cash	9.10	154.08	52.99	60.41
Price / Book	1.66	8.26	10.69	6.18
Net Income	$1.29B	$23.83M	$3.59B	$332.29M
7 Day Performance	3.43%	-3.47%	-2.20%	-2.05%
1 Month Performance	4.79%	2.69%	1.63%	-2.18%
1 Year Performance	64.81%	45.93%	25.64%	17.67%

Biogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIIB Biogen	3.7448 of 5 stars	$205.99 -1.4%	$220.04 +6.8%	+64.8%	$30.41B	$9.89B	22.10	7,500	Analyst Forecast
AMGN Amgen	4.0318 of 5 stars	$360.45 -0.8%	$356.62 -1.1%	+24.3%	$194.54B	$36.75B	25.08	31,500	Trending News Analyst Downgrade Analyst Revision
DNLI Denali Therapeutics	3.3266 of 5 stars	$26.48 +3.1%	$34.75 +31.2%	+66.4%	$4.20B	$330.53M	N/A	430	Analyst Forecast
GILD Gilead Sciences	4.795 of 5 stars	$131.40 +1.2%	$159.04 +21.0%	+24.1%	$163.14B	$29.44B	17.90	17,000	Analyst Revision
IONS Ionis Pharmaceuticals	3.5564 of 5 stars	$56.75 -2.6%	$96.05 +69.3%	+30.2%	$9.38B	$944M	N/A	1,402	Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIIB) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Summary

How does Biogen compare to Denali Therapeutics?

Summary

How does Biogen compare to Gilead Sciences?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Summary

How does Biogen compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Which has more volatility and risk, BIIB or AMGN?

Is BIIB or AMGN more profitable?

Does the media refer more to BIIB or AMGN?

Do institutionals & insiders hold more shares of BIIB or AMGN?

Which has stronger valuation & earnings, BIIB or AMGN?

Do analysts prefer BIIB or AMGN?

Summary

How does Biogen compare to Denali Therapeutics?

Which has higher valuation and earnings, BIIB or DNLI?

Do analysts rate BIIB or DNLI?

Is BIIB or DNLI more profitable?

Does the media prefer BIIB or DNLI?

Do insiders and institutionals hold more shares of BIIB or DNLI?

Which has more risk and volatility, BIIB or DNLI?

Summary

How does Biogen compare to Gilead Sciences?

Does the media prefer GILD or BIIB?

Is GILD or BIIB more profitable?

Do analysts rate GILD or BIIB?

Do institutionals and insiders hold more shares of GILD or BIIB?

Which has better valuation & earnings, GILD or BIIB?

Which has more volatility & risk, GILD or BIIB?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Is BIIB or IONS more profitable?

Which has higher valuation and earnings, BIIB or IONS?

Which has more volatility & risk, BIIB or IONS?

Do insiders & institutionals believe in BIIB or IONS?

Do analysts prefer BIIB or IONS?

Does the media prefer BIIB or IONS?

Summary

How does Biogen compare to Moderna?

Do analysts rate MRNA or BIIB?

Does the media favor MRNA or BIIB?

Which has stronger valuation & earnings, MRNA or BIIB?

Is MRNA or BIIB more profitable?

Do insiders and institutionals hold more shares of MRNA or BIIB?

Which has more volatility & risk, MRNA or BIIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools